TIGIT, CD155, & CD226
Promising Targets for Cancer Immunotherapies
It’s possible someone you know has benefited from cancer treatments based on checkpoint receptors. Therapeutic antibodies targeting PD-1 and CTLA-4 pathways have already added years to the lives of lucky patients. Unfortunately, not everyone responds to these treatments. This resistance drives the search for new therapies to extend the successes of existing PD-1 and CTLA-4-based treatme...
Methods For Drug Discovery
Immunotherapies based on targeting the PD-1:PD-L1 immune checkpoint pathway are having clinical impact and are giving new hope to cancer patients. However, positive response to treatment is not guaranteed and resistance remains a concern. Improving outcomes based on immunotherapy requires multiple approaches for manipulating the complexities of the immune system and tumor microenvironment. To meet these challenges, a series of r...
The Promise of NK Cell Therapeutics
Introduction
NK cells are the first line of defense against cancer and have been in the spotlight as a cancer therapy in the last decade. Their advantages versus T cells, such as their safety profile and not requiring MHC (Major Histocompatibility Complex)-antigen stimulation to become cytotoxic, have made NK cells attractive. However, as with T cells, the TME (tumor microenvironment) can suppress their activity, and infiltration into solid tumors is s...
Immunotherapy Biochemical Screening Services
Immunotherapy is a type of medical treatment that engages the body's immune system to fight diseases, such as cancer, infections, and autoimmune disorders. It works by either stimulating the immune system to attack cancer cells or other disease-causing agents, or by using synthetic proteins or antibodies to target specific molecules on the surface of cancer cells or other pathogens. Immunotherapy has shown prom...
